Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Susceptibility of Clinical Staphylococcus aureus Small-Colony Variants to β-Lactam and Non-β-Lactam Antibiotics

Evgeny A. Idelevich, André Kriegeskorte, Nina Schleimer, Georg Peters, Christof von Eiff, Karsten Becker
Evgeny A. Idelevich
aInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Kriegeskorte
aInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Schleimer
aInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Peters
aInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christof von Eiff
aInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karsten Becker
aInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karsten Becker
DOI: 10.1128/AAC.02532-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The Staphylococcus aureus small-colony variant (SCV) phenotype has been associated with relapsing and antibiotic-refractory infections. However, little is known about the activities of antibiotics on clinical SCVs. Here, we demonstrated that SCVs without detectable auxotrophies were at least as susceptible to most β-lactam and non-β-lactam antibiotics in vitro as their corresponding clonally identical strains with a normal phenotype. After prolonged incubation, a regrowth phenomenon has been observed in gradient diffusion inhibition zones irrespective of the strains' phenotype.

TEXT

Staphylococcus aureus represents one of the major invasive pathogens causing a wide range of clinically important and life-threatening infections worldwide (1). Small-colony variants (SCVs) represent a naturally occurring slow-growing subpopulation of S. aureus associated with chronic and recurrent courses of infection (2). The SCV phenotype is characterized by an altered metabolism as an adaptation to their intracellular lifestyle (3–5). β-Lactam antibiotics (BLAs), especially penicillinase-stable penicillins or first- and second-generation cephalosporins, are antimicrobials of choice for the treatment of severe S. aureus infections unless methicillin-resistant S. aureus (MRSA) is involved (6). Most of the data on the susceptibility of S. aureus SCVs toward β-lactams and other antibiotics have been derived from studies performed with deletion mutants mimicking the SCV phenotype or SCV isolates colonizing the airways of cystic fibrosis patients (7–9). However, only little is known about the effects of BLAs on S. aureus SCVs recovered from clinical samples. In this study, we investigated the susceptibilities of stable clinical SCVs and their corresponding clonally identical clinical strains with a normal phenotype (NP) toward a broad set of BLAs and non-BLAs.

(This work was presented in part at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 9 to 12 September 2012 [10].)

Ten methicillin-susceptible S. aureus (MSSA) strain pairs recovered from clinical samples (skin and soft tissue infections, bone and joint infections, wound infections, and intra-abdominal infections) at the University Hospital Münster, Germany, were included. Isolates from cystic fibrosis patients were excluded. Each strain pair consisted of a stable SCV and its corresponding NP for which clonality was confirmed by pulsed-field gel electrophoresis (11, 12). Since spontaneous switching of SCVs into the NP is possible (13), stable phenotypes were confirmed by observation of colony morphology during the experiments. Auxotrophy testing was performed as described elsewhere (9) using 10 μl of hemin (1 mg/ml), menadione (160 μg/ml), and thymidine (100 μg/ml; Sigma-Aldrich, Inc., St. Louis, MO, USA) and Mueller-Hinton agar (MHA; Merck KGaA, Darmstadt, Germany). None of the SCVs exhibited auxotrophy for the tested substances. In addition to clinical strain pairs, genetically defined stable hemB- and thyA-knockout mutants of MSSA laboratory strains 8325-4 and SH1000, respectively, and their corresponding parental and complemented mutant (CM) strains were tested (14, 15). Furthermore, MSSA reference strain ATCC 29213 was included as a quality control.

The MICs of 12 BLAs and 13 non-BLAs (Table 1) were determined by the gradient diffusion method (Etest; bioMérieux, Marcy-l'Étoile, France), according to the manufacturer's recommendations. Briefly, a bacterial suspension was prepared from colonies growing overnight on solid medium and adjusted to a turbidity of 0.5 McFarland. This inoculum was streaked onto MHA (Merck KGaA) using a plate rotator (type EPA; Robin SA, Beaucouzé, France). Etest strips were applied within 15 min after the excess moisture dried. For clinical SCVs not growing on MHA as well as for the thyA-knockout mutant, MHA with 5% sheep blood (Merck KGaA, Darmstadt, Germany) was used. The MICs were read and documented after 18 h of incubation at 36°C and for oxacillin and vancomycin after 24 h, according to the recommendations of the manufacturer. Since SCVs exhibit deficient growth, MICs were also read after 48 h of incubation. The results were read by three investigators, and median MICs were calculated for analysis. Since the appearance of single colonies in the inhibition zone was observed after prolonged incubation in the preliminary experiments, the plates were further incubated and read every 24 h for a total period of 7 days to check for appearance of colonies in the inhibition zone, indicating surviving cells.

View this table:
  • View inline
  • View popup
TABLE 1

MICs of 10 clinical S. aureus strain pairs consisting of SCVs and their clonally identical parental isolates with NP

For most tested BLAs, the MIC50 and MIC90 were either equal to or slightly lower for clinical SCVs than for the corresponding NPs (Table 1). The same applied to the MICs for hemB and thyA mutants compared to their wild types (Table 2). Since incubation was performed for 48 h, considerable MIC reading bias due to slower growth of SCVs is unlikely. As expected for MSSA, all strain pairs were susceptible to cefoxitin and oxacillin, with SCVs showing MICs slightly lower than those for NPs. The hemB and thyA mutants also exhibited oxacillin MICs lower than those of corresponding NPs and CMs. This is in accordance with earlier reports assessing the MICs of defined hemB mutant strains (16, 17). The cefoxitin MICs of the tested mutants were comparable to those from corresponding NPs and CMs. Interestingly, intracellular forms of menD mutant SCVs were shown to be hypersusceptible to BLAs in a recent study (18).

View this table:
  • View inline
  • View popup
TABLE 2

MICs of β-lactam and non-β-lactam antibiotics determined with Etest for two S. aureus triplets consisting of isolates with NP, their isogenic knockout mutants with an SCV phenotype, and their CMs

The MIC50s of most non-BLAs were identical to or slightly lower for clinical SCVs than for NPs, whereas the MIC90 values for most non-BLAs were identical or slightly higher for SCVs than for NPs. In seven of 10 pairs, the SCV strains had slightly or considerably lower MICs for gentamicin than their corresponding NP strains after 18 h of incubation (see Table S1 in the supplemental material). This finding is in contrast to those of prior reports about the reduced susceptibility of SCVs to aminoglycosides (9, 11, 19, 20) and may suggest that most clinical SCVs tested here exhibited an intact electron transport, which implies functional aminoglycoside uptake (21). However, we also found SCVs with higher gentamicin MICs than those of their NPs in two strain pairs, resulting in categorization as resistant, while the corresponding NPs were susceptible (Table S1). The hemB mutant exhibited a higher MIC for gentamicin than for their corresponding NP and CM (Table 2). This is in accordance with previous findings (14, 16, 17, 22) and is explained by electron transport deficiencies due to the hemB knockout. Interestingly, Garcia et al. postulated that gentamicin used in cell culture-based experiments remained highly bactericidal against genetically defined electron transport-deficient SCVs in spite of its increased MIC (7). For the thyA mutant, the gentamicin MICs were similar to those of corresponding NP and CM as described before for strains with mutations in thyA (23). For other tested non-BLAs, the SCV mutants exhibited no major differences from NPs and CMs irrespective of their knockouts, except for clarithromycin and clindamycin, toward which the mutants showed, as expected, resistance due to allelic replacement of hemB or thyA genes by erythromycin resistance cassette ermB (Table 2).

For some strains, we observed a regrowth phenomenon occurring as single colonies in the inhibition zone of several antibiotics. Typically, the regrown colonies appeared circularly in a concentration-dependent manner surrounding the Etest strip (Fig. 1) after prolonged incubation of up to 7 days. The regrowth was found more frequently with BLAs (19.2%) (Fig. 1 and Table 1). However, there were no marked differences between clinical NPs (17.5%) and SCVs (20.8%) regarding the occurrence of this phenomenon (Table 1). The regrowth colonies observed may result from survived persister cells. Further detailed investigations of this phenomenon are warranted, which should incorporate time-kill studies to investigate the impact of the slow growth of SCVs on killing kinetics.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Example of regrown S. aureus colonies (normal phenotype) in the inhibition zone of oxacillin gradient diffusion test appearing on day 6 (just becoming visible) and day 7. Inset, 3-fold magnification of regrown colonies on day 7.

In conclusion, BLAs and other antibiotics used in this study showed high in vitro activities against a diverse set of clinical MSSA-SCVs. Thus, the detection of SCVs in clinical samples should not curtail a priori the choice of appropriate antibiotics. Clinical studies on optimal treatment regimens for SCV-associated infections are warranted.

ACKNOWLEDGMENTS

We are grateful to B. Grünastel and M. Tigges for their expert technical assistance.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

We declare no conflicts of interest.

FOOTNOTES

    • Received 12 December 2017.
    • Returned for modification 4 January 2018.
    • Accepted 19 January 2018.
    • Accepted manuscript posted online 29 January 2018.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.02532-17.

  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Tong SYC,
    2. Davis JS,
    3. Eichenberger E,
    4. Holland TL,
    5. Fowler VG, Jr
    . 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–661. doi:10.1128/CMR.00134-14.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Proctor RA,
    2. von Eiff C,
    3. Kahl BC,
    4. Becker K,
    5. McNamara P,
    6. Herrmann M,
    7. Peters G
    . 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295–305. doi:10.1038/nrmicro1384.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kriegeskorte A,
    2. König S,
    3. Sander G,
    4. Pirkl A,
    5. Mahabir E,
    6. Proctor RA,
    7. von Eiff C,
    8. Peters G,
    9. Becker K
    . 2011. Small colony variants of Staphylococcus aureus reveal distinct protein profiles. Proteomics 11:2476–2490. doi:10.1002/pmic.201000796.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. von Eiff C,
    2. McNamara P,
    3. Becker K,
    4. Bates D,
    5. Lei X-H,
    6. Ziman M,
    7. Bochner BR,
    8. Peters G,
    9. Proctor RA
    . 2006. Phenotype microarray profiling of Staphylococcus aureus menD and hemB mutants with the small-colony-variant phenotype. J Bacteriol 188:687–693. doi:10.1128/JB.188.2.687-693.2006.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Kriegeskorte A,
    2. Grubmüller S,
    3. Huber C,
    4. Kahl BC,
    5. von Eiff C,
    6. Proctor RA,
    7. Peters G,
    8. Eisenreich W,
    9. Becker K
    . 2014. Staphylococcus aureus small colony variants show common metabolic features in central metabolism irrespective of the underlying auxotrophism. Front Cell Infect Microbiol 4:141. doi:10.3389/fcimb.2014.00141.
    OpenUrlCrossRef
  6. 6.↵
    1. Idelevich EA,
    2. Kreis C,
    3. Löffler B,
    4. Peters G
    . 2017. Staphylococcus aureus-associated musculoskeletal infections, Curr Top Microbiol Immunol 409:229–261. doi:10.1007/82_2016_19.
    OpenUrlCrossRef
  7. 7.↵
    1. Garcia LG,
    2. Lemaire S,
    3. Kahl BC,
    4. Becker K,
    5. Proctor RA,
    6. Denis O,
    7. Tulkens PM,
    8. Van Bambeke F
    . 2012. Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Antimicrob Agents Chemother 56:3700–3711. doi:10.1128/AAC.00285-12.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Nguyen HA,
    2. Denis O,
    3. Vergison A,
    4. Theunis A,
    5. Tulkens PM,
    6. Struelens MJ,
    7. Van Bambeke F
    . 2009. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother 53:1434–1442. doi:10.1128/AAC.01145-08.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kahl B,
    2. Herrmann M,
    3. Everding AS,
    4. Koch HG,
    5. Becker K,
    6. Harms E,
    7. Proctor RA,
    8. Peters G
    . 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 177:1023–1029. doi:10.1086/515238.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Idelevich EA,
    2. Kriegeskorte A,
    3. von Eiff C,
    4. Peters G,
    5. Becker K
    . 2012. In vitro susceptibility and tolerance of Staphylococcus aureus small colony variants to beta-lactam antibiotics, abstr E-1483. 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA, 9 to 12 September 2012.
  11. 11.↵
    1. von Eiff C,
    2. Bettin D,
    3. Proctor RA,
    4. Rolauffs B,
    5. Lindner N,
    6. Winkelmann W,
    7. Peters G
    . 1997. Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis. Clin Infect Dis 25:1250–1251. doi:10.1086/516962.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Goering RV,
    2. Winters MA
    . 1992. Rapid method for epidemiological evaluation of Gram-positive cocci by field inversion gel electrophoresis. J Clin Microbiol 30:577–580.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. von Eiff C,
    2. Becker K,
    3. Skov RL
    . 2015. Staphylococcus, Micrococcus, and other catalase-positive cocci, p 354–382. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of clinical microbiology, 11th ed. ASM Press, Washington, DC.
  14. 14.↵
    1. von Eiff C,
    2. Heilmann C,
    3. Proctor RA,
    4. Woltz C,
    5. Peters G,
    6. Götz F
    . 1997. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol 179:4706–4712. doi:10.1128/jb.179.15.4706-4712.1997.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kriegeskorte A,
    2. Block D,
    3. Drescher M,
    4. Windmüller N,
    5. Mellmann A,
    6. Baum C,
    7. Neumann C,
    8. Lorè NI,
    9. Bragonzi A,
    10. Liebau E,
    11. Hertel P,
    12. Seggewiss J,
    13. Becker K,
    14. Proctor RA,
    15. Peters G,
    16. Kahl BC
    . 2014. Inactivation of thyA in Staphylococcus aureus attenuates virulence and has a strong impact on metabolism and virulence gene expression. mBio 5:e01447-14. doi:10.1128/mBio.01447-14.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Brouillette E,
    2. Martinez A,
    3. Boyll BJ,
    4. Allen NE,
    5. Malouin F
    . 2004. Persistence of a Staphylococcus aureus small-colony variant under antibiotic pressure in vivo. FEMS Immunol Med Microbiol 41:35–41. doi:10.1016/j.femsim.2003.12.007.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Moisan H,
    2. Brouillette E,
    3. Jacob CL,
    4. Langlois-Bégin P,
    5. Michaud S,
    6. Malouin F
    . 2006. Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB. J Bacteriol 188:64–76. doi:10.1128/JB.188.1.64-76.2006.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Garcia LG,
    2. Lemaire S,
    3. Kahl BC,
    4. Becker K,
    5. Proctor RA,
    6. Tulkens PM,
    7. Van Bambeke F
    . 2012. Intracellular forms of menadione-dependent small-colony variants of methicillin-resistant Staphylococcus aureus are hypersusceptible to β-lactams in a THP-1 cell model due to cooperation between vacuolar acidic pH and oxidant species. J Antimicrob Chemother 67:2873–2881. doi:10.1093/jac/dks325.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Lewis LA,
    2. Li K,
    3. Bharosay M,
    4. Cannella M,
    5. Jorgenson V,
    6. Thomas R,
    7. Pena D,
    8. Velez M,
    9. Pereira B,
    10. Sassine A
    . 1990. Characterization of gentamicin-resistant respiratory-deficient (res-) variant strains of Staphylococcus aureus. Microbiol Immunol 34:587–605. doi:10.1111/j.1348-0421.1990.tb01035.x.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Baumert N,
    2. von Eiff C,
    3. Schaaff F,
    4. Peters G,
    5. Proctor RA,
    6. Sahl H-G
    . 2002. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb Drug Resist 8:253–260. doi:10.1089/10766290260469507.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Mates SM,
    2. Eisenberg ES,
    3. Mandel LJ,
    4. Patel L,
    5. Kaback HR,
    6. Miller MH
    . 1982. Membrane potential and gentamicin uptake in Staphylococcus aureus. Proc Natl Acad Sci U S A 79:6693–6697. doi:10.1073/pnas.79.21.6693.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Mitchell G,
    2. Gattuso M,
    3. Grondin G,
    4. Marsault É,
    5. Bouarab K,
    6. Malouin F
    . 2011. Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 55:1937–1945. doi:10.1128/AAC.01468-10.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Besier S,
    2. Zander J,
    3. Siegel E,
    4. Saum SH,
    5. Hunfeld K-P,
    6. Ehrhart A,
    7. Brade V,
    8. Wichelhaus TA
    . 2008. Thymidine-dependent Staphylococcus aureus small-colony variants: human pathogens that are relevant not only in cases of cystic fibrosis lung disease. J Clin Microbiol 46:3829–3832. doi:10.1128/JCM.01440-08.
    OpenUrlAbstract/FREE Full Text
  24. 24.
    European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf.
  25. 25.
    1. Novick R
    . 1967. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 33:155–166. doi:10.1016/0042-6822(67)90105-5.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.
    1. Horsburgh MJ,
    2. Aish JL,
    3. White IJ,
    4. Shaw L,
    5. Lithgow JK,
    6. Foster SJ
    . 2002. σB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from Staphylococcus aureus 8325-4. J Bacteriol 184:5457–5467. doi:10.1128/JB.184.19.5457-5467.2002.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Susceptibility of Clinical Staphylococcus aureus Small-Colony Variants to β-Lactam and Non-β-Lactam Antibiotics
Evgeny A. Idelevich, André Kriegeskorte, Nina Schleimer, Georg Peters, Christof von Eiff, Karsten Becker
Antimicrobial Agents and Chemotherapy Mar 2018, 62 (4) e02532-17; DOI: 10.1128/AAC.02532-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Susceptibility of Clinical Staphylococcus aureus Small-Colony Variants to β-Lactam and Non-β-Lactam Antibiotics
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Susceptibility of Clinical Staphylococcus aureus Small-Colony Variants to β-Lactam and Non-β-Lactam Antibiotics
Evgeny A. Idelevich, André Kriegeskorte, Nina Schleimer, Georg Peters, Christof von Eiff, Karsten Becker
Antimicrobial Agents and Chemotherapy Mar 2018, 62 (4) e02532-17; DOI: 10.1128/AAC.02532-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Staphylococcus aureus
small-colony variants
β-lactam antibiotics
susceptibility
resistance
aminoglycosides
antibiotic resistance
daptomycin
lincosamides
linezolid
trimethoprim

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596